VTGN News and Press, VistaGen Therapeutics Inc. From 10/17/23

2023-10-17 08:26:49 ET SciSparc  ( SPRC ) +105% . AgriFORCE Growing Systems  ( AGRI ) +34% . Monte Rosa Therapeutics  ( GLUE ) +17% Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and...

2023-10-06 08:15:27 ET Gainers: Pioneer Natural Resources ( PXD ) +10% close to buying Pioneer Natural for about $60B - WSJ (update). Akso Health Group  ( AHG ) +8% . Connexa Sports Technologies  ( CNXA ) +7% . Apellis Pharmaceuticals ...

Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will be presenting at the upcoming Jefferies Biotech...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the Company will present and host one-on-one meetings at the...

Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offe...

2023-10-02 07:48:12 ET Vistagen Therapeutics ( NASDAQ: VTGN ) has priced $100M underwritten offering at a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant. The offering consists of 15,010,810 common shares, accompa...

Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the...

Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, is reporting on study results for PH80, one of its f...

PH80 nasal spray demonstrated statistically and clinically significant improvement versus placebo in an exploratory double-blind, placebo-controlled Phase 2A study (n=52) in subjects with a history of premenstrual dysphoric disorder (PMDD) PH80 was well-tolerated with an adverse event pro...

Vistagen (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders. Together with Fuji Pharma Co. (TSE: 4554), a pharmaceutical company ...